The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days. MAIN OUTCOMES AND MEASURES: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. RESULTS: Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively). CONCLUSIONS AND RELEVANCE: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800968.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF)”
From Safety of Semaglutide (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Furthermore, 2 small randomized clinical trials of liraglutide in patients with HF with reduced EF, 1 of which enrolled patients with recent HF hospitalization, suggested potential harm of liraglutide, although neither trial found statistically significant differences.36,37”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [36]
In the citing paper
“In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.181”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Anand, I. S., Fisher, L. D., Chiang, Y., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 857
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 706
Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2)
von Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00574-0 · Cited by 1
Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
Arnott, C. G., & Neal, B. C. (2019) · Circulation · doi:10.1161/circulationaha.119.043303 · Cited by 1
Which Drug Will “Lead” in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?
Dec, G. W. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.062 · Cited by 1
Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes
Seferovic, P. M., Polovina, M. M., Seferović, J. P., & Rosano, G. M. C. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.019 · Cited by 1
Banerjee, M., Maisnam, I., & Mukhopadhyay, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad506 · Cited by 1
Diabetes and Heart Failure in the Crosshairs: Where is the Target?
Ezekowitz, J. A., & Armstrong, P. W. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.703
Halimi, S. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30052-4
Diabetes and the cardiovascular system
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch6
Perspectives on medical treatment of type 2 diabetes mellitus
Yoshioka, N. (2017) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.23.015
Rau, M., & Lehrke, M. (2017) · Der Klinikarzt · doi:10.1055/s-0043-113349
Seguridad de los fármacos antidiabéticos en pacientes con insuficiencia cardiaca
Carrasco-Sánchez, F. J., Ostos-Ruiz, A. I., & Soto-Martín, M. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.07.007
Safety of diabetes drugs in patients with heart failure
Carrasco-Sánchez, F. J., Ostos-Ruiz, A. I., & Soto-Martín, M. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.07.002
Bois, J. P., & Gropler, R. J. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1068-8
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1423962 · Cited by 1
Multiple Outcomes in Heart Failure Research: Composite Endpoints and Multivariate Modelling
Brown, P. M. (2017) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3901zt68
Therapie des Diabetes bei Herzinsuffizienz
Kappel, B. A., & Lehrke, M. (2019) · Diabetes aktuell · doi:10.1055/a-0833-1043
Heart Failure and Metabolic Factors
Nilsson, P. M., Molvin, J., & Magnusson, M. (2019) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-93320-7_8
Seferovic, P. M., & Jhund, P. S. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz219
Diabetic retinopathy: a tool for cardiovascular risk stratification
Avogaro, A., & Fadini, G. P. (2020) · Diabetes Mellitus · doi:10.14341/dm10372
Heart failure in patients with diabetic cardiomyopathy: modern methods of treatment
Zhuravlyova, L., Sokolnikova, N. V., & Rogachova, T. (2020) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2020.01.022
Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten
Kahles, F., & Lehrke, M. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2125
Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure
Schumacher, C., Dril, E. V., Shealy, K. M., & Goldman, J. D. (2020) · Clinical Diabetes · doi:10.2337/cd20-0008 · Cited by 1
Novel pharmacotherapies for heart failure
Rajapreyar, I. N., Lenneman, A., & Prabhu, S. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813706-2.00018-x
Battise, D. M., & Olin, J. L. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000516
Murín, J., Bulas, J., & Wawruch, M. (2020) · Klinická farmakologie a farmacie · doi:10.36290/far.2020.028
Bourron, O., & Phan, F. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.016
Von glukozentrischen zu kardio- und renozentrischen Behandlungsoptionen bei Typ‑2‑Diabetes
Chakaroun, R. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00831-y
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Agarwalla, A., Gruen, J., Peters, C. J., Sinnenberg, L. E., OWENS, A. T., & Reza, N. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.31
Thakkar, H. V., & Negishi, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64067-1.00028-0
Jamieson, A. (2022) · doi:10.1093/med/9780198766223.003.0035
Adipositas und Herzinsuffizienz
Kresoja, K., Thiele, H., & Lurz, P. C. (2022) · CardioVasc · doi:10.1007/s15027-022-3673-y
Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure
Mirzazada, V., kizi, S. S. S., Ismayilova, N., Huseynova, A., Nurmammadova, G., Ismayilova, S., & Aliyeva, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106391
Can subgroup analyses in randomized trials guide individualized patient care?
Aronson, D. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2710
Heart Failure and Cardiac Dysfunction in Diabetes
Afari, M. E., & Givertz, M. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_27
Self-citationComments on the myPACE Randomized Clinical Trial
Rodolico, D., & Schiattarella, G. G. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1743
Demidova, T. Y., Titova, V. V., & Izmaylova, M. Y. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202425
Pandey, A., Patel, K. V., & Verma, S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch50
Treatment of Clusters of Risks to Prevent Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.12.008
A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024Preprint
Liao, T., Wang, C., Tan, X., Xie, G., Liu, X., & Ouyang, F. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4822553
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_3
Bewährtes und Neues in der Therapie der Herzinsuffizienz
Schwenger, V. (2025) · Die Nephrologie · doi:10.1007/s11560-024-00821-3
韦, 继. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.152481
Zhang, Z., Liu, S., Xian, J., Zhang, Y., Zhang, C., Wang, Z., Deng, H., Feng, J., & Yao, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26154
Racial Differences in Advanced Heart Failure Patients
Mark, J. D., Batista, J. L., Shah, M. K., Makuvire, T. T., Latif, Z., Colombo, R. A., Llanos, A., Ibrahim, N. E., & DeFilippis, E. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.005
Self-citationThe Role of GLP-1R and GIPR Agonism in Heart Failure
Sedrak, P., & Connelly, K. A. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3138
Hammer, Y., Arbel, R., Razi, T., Netzer, D., Weinstein, J. M., & Iakobishvili, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6768681/v1
Research Progress of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Heart Failure
胡, 明. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1571991
Prajapati, P., Shafi, N., Pachchipulusu, V., Fatima, N., Noorien, S., Biswas, S. K., Narula, A., Aishwarya, K., Prajapati, S. D., Patel, M. K., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334855
Umar, M., Zaheer, M., & Ghani, Z. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133871
El‐Sheikh, M., Sillassen, C. D. B., Wisborg, F. D., Hove, J. D., Dirksen, C., Lee, M. M. Y., Jakobsen, J. C., & Grand, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103668 · Cited by 1
Rai, A., Kolli, M., Singh, G. P., Rishu, R., Cai, C. Y. L., Balaji, H., Pongen, B., Joy, S., & Shahid Sai, A. K. (2025) · Cureus · doi:10.7759/cureus.96162
Metabolomic signature of weight loss and association with heart failurePreprint
Sunderland, N. P., Smith, M. L., McConnachie, A., Welsh, P. I., Taylor, R., Lean, M. E. J., Rogers, C. A., Blazeby, J. M., Sattar, N. A., Paternoster, L., et al. (2025) · medRxiv · doi:10.1101/2025.11.14.25340254
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Figshare · doi:10.6084/m9.figshare.16696428
Nogueira, A. C. C., Barreto, J., Moura, F. A., Luchiari, B., Abuhab, A., Bonilha, I., Nadruz, W., Gaziano, J. M., Gaziano, T. A., de Carvalho, L. S. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26631928
Diabetes and cancer: therapeutic implications
Fay, S., Bayshtok, G., HAMO, C. E., Butler, J., & Bloom, M. W. (2026) · Cardio-Oncology · doi:10.1186/s40959-025-00412-8
Siddiqi, T. J., Khan, M. M., Fonarow, G. C., Butler, J., & Greene, S. J. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf004
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528
Ferreira, V. M., & Muller, V. A. (2026) · medRxiv · doi:10.64898/2026.02.10.26345946
Echocardiographic evaluation and clinical implications of cardiac remodeling in obesity
Okushi, Y., Takahashi, T., & Kusunose, K. (2026) · Journal of Echocardiography · doi:10.1007/s12574-026-00721-6
Prevention of Heart Failure in People With Diabetes
Pandey, A., & Hernandez, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00015-x
Self-citationMarx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Costa, T. A., Vest, A. R., & Harrington, J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001284
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Costa, T. A., Harrington, J., Nelson, A. J., Pandey, A., Neeland, I. J., Lee, M. M. Y., Kang, Y. M., & McGuire, D. K. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01138-1
Liu, W., Shang, L., Li, P., Yao, Y., Yin, H., Zhang, H., Liu, Z., & Guo, Y. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03170-8
A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
Kordi, N., Kheirandish, R., Akraminia, P., Jung, F., & Karami, S. (2025) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291251414840
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie
Busti, M. D., Canonico, M. E., Keramida, K., Palazzuoli, A., Kato, E. T., Sakata, Y., Alexy, T., Grupper, A., Nodari, S., Ojji, D. B., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10627-1
Yousafzai, O. K., Kanwal, K., Annie, F., & Rinehart, S. (2026) · medRxiv · doi:10.64898/2026.04.13.26350824
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
Cardiac GLP1R gene expression: A cross-species single-cell transcriptomic analysis
Dostal, C., Ernst, M., Reiner, J., Snelling, R., Hu, C., Pokreisz, P., Kiss, A., & Podesser, B. K. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00113
Biegus, J. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag131
Chen, Z., Yang, Q., Liu, J. S., Zhao, H., Ying, H., Liu, H., Huang, L., Lin, H. Y., Wang, S., Li, M., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04888-8
Obesity and Outcomes in Heart Failure
Özkan, B., Neeland, I. J., & Ndumele, C. E. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.001
Christophides, T., Figlioli, G., Christoforou, S., Ioannou, K., Kounnafi, M., Piovani, D., Bonovas, S., & Nikolopoulos, G. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124450
Ferreira, V. M., & Muller, V. A. (2026) · Cureus · doi:10.7759/cureus.110621
Waqas, S. A., Ibrahim, M., Ahmed, M., Waqas, M., Aamir, J., Fudim, M., Musani, M. H., Fonarow, G. C., & Greene, S. J. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01969-6 · Cited by 1
Ramadan, A., Aglan, A., Salama, B., Abdalla, M., Fath, A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001322
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
What’s new in heart failure? June 2026
Markwirth, P., Hoevelmann, J., Tokcan, M., & Haring, B. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag204
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Sun, W.-T., Liu, R., Jiang, Y.-H., Zhao, Y., Yi‐Cai, Wu, Y. T., Li, T., & Chang, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71094
Tristan, C. D., Irnizarifka, I., Kynaya, E. M., Gani, M., Wijayanto, M. A., Asrial, A. A., & Pranata, R. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00812-w
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Ahsan, M., Mazhar, S., Zafar, H., Mansoor, H., Nancy, F., Abbas, S. M., Shaikh, H., Khan, D. Z., Khan, A., Zahoor, B., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70246
The Skinny on the Use of GLP‐1 Receptor Agonists in Peripheral Artery Disease
Beckman, J. A., & Annex, B. H. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.052332
Shirmohamadi, E., Ghasemloo, N., Ebrahimi, N., Mohammadzadeh, N., Ehtemami, A., Babaei, M., & Fardoost, S. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70311
Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations
Pathan, F. K., & Williams, K. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.05
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Li, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
Al-Nusair, M., Maini, A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363576
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Yuan, Y., Chen, C., Li, X., Guo, J., Liu, Q., Lin, Y., Sun, L., & Fan, G. (2026) · Drugs · doi:10.1007/s40265-026-02380-4
Sicouri, N., Brecher, V., Androutsopoulou, V., Brizzio, M., Zotos, P.-A., Baudo, M., & Sicouri, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197489
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
Gargiulo, P., Marzano, F., Liccardi, L., Nodari, S., Cameli, M., Giallauria, F., Guerra, F., Imbalzano, E., Sinagra, G., Carugo, S., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107183
Metadata
- Authors
- Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., McNulty, S. E., Anstrom, K. J., Shah, M. R., Braunwald, E., Cappola, T. P., & for the NHLBI Heart Failure Clinical Research Network
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Mayo Clinic (US)
- Brigham and Women's Hospital (US)
- University Hospitals of Cleveland (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University (US)
- Tufts University (US)
- National Heart, Lung, and Blood Institute (US)
- Brigham and Women’s Hospital, Boston, Massachusetts
- Corresponding author
- Margulies, Kenneth B.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-02
- Volume
- 316
- Issue
- 5
- Pages
- 500
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5021525
- OpenAlex
- W2505843168
- Cited by
- 706
- References
- 24
- Citations by year
- 2026: 85 · 2025: 99 · 2024: 75 · 2023: 58 · 2022: 46 · 2021: 50 · 2020: 77 · 2019: 68 · 2018: 78 · 2017: 56 · 2016: 13
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL110297, U10HL110342, U10HL084904, U10HL110262, U01HL084861, U10HL110309, U10HL110336, U10HL110302, U10HL110337, U10HL110312, U10HL110338)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, GLP-1 receptor agonists, advanced heart failure, reduced left ventricular ejection fraction, clinical stability, heart failure readmission, mortality, NT-proBNP, myocardial metabolism, type 2 diabetes, cardiac structure and function, 6-minute walk distance, quality of life, subcutaneous injection, cardioprotection
- MeSH terms
- Liraglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Patient Readmission, Quality of Life, Stroke Volume, United States, Odds Ratio, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
